Cervical cancer is the second most common cancer in women worldwide and the leading gynaecological malignancy in women in Africa.1 In 2008 the International Agency for Research on Cancer estimated that 493 243 women are newly diagnosed with cervical cancer annually. Of these, more than 273 000 die each year.1,2 It is estimated that around 80 000 women, of whom 60 000 die each year, live in Africa. Because there are inadequate cancer registries in many African countries, it is likely that these figures are a gross under-representation.Infection of the cervix with high-risk human papillomavirus (HPV) is regarded as the main causal factor in cervical cancer.
3There are more than 150 genotypes of HPV with around 40 known to infect the anogenital tract, giving rise to genital warts or neoplastic lesions.3 Recently, 2 prophylactic vaccines against the main highrisk HPV variants, 16 and 18, have been introduced by Merck & Company (Gardasil) and GlaxoSmithKline (Cervarix). These induce an immune response that blocks initial HPV infection and confers protection against cancer associated with HPV 16 and 18 and some closely related variants. These have limited benefit for women already infected with high-risk HPV and in addition are out of reach of the majority of women in Africa due to the high costs involved. Although HPV infection initiates disease, cervical cancer is a multi-step process, with other contributing factors, including multiple sexual partners, tobacco carcinogens, a weakened immune system and sexually transmitted infection by human immunodeficiency virus (HIV), Chlamydia trachomatis and Neisseria gonorrhoeae, thought to contribute to the aetiology.HPV initially infects basal keratinocytes and epithelial cells and uses the host's cellular machinery for replication and persistence. 4 The HPV genome consists of 3 domains, a non-coding upstream region, an early region containing open reading frames E1, E2, E4, E5, E6 and E7, and a late region encoding the major and minor capsid proteins. 4 In the vast majority of women, infections and HPV-induced lesions are transient and are naturally resolved. However, approximately 10 -20% of women fail to eliminate the virus. 4 In these cases, persistence of infection, viral integration and activation of inflammatory pathways have been linked to neoplastic transformation and malignant progression. 4,5 In this review, we highlight our findings relating to the activation of inflammatory pathways in cervical cancers and address their role in disease progression.
Persistent HPV infection and inflammationBy broad definition, inflammation involves tissue remodelling events brought about by alterations to epithelial, vascular and immune cell function. These are orchestrated by specific molecular pathways involving a host of cytokines, chemokines, growth factors and lipid mediators. 6 Compelling evidence has shown that the majority of cancers arise from sites of chronic irritation, infection and inflammation, 7 solidifying the concept that chronic unabated inflammation is critic...